Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Alzheimer's Association commends U.S. House Representatives for new legislation

Alzheimer's Association commends U.S. House Representatives for new legislation

Scientists discover new class of compounds that selectively block 'serine hydrolases'

Scientists discover new class of compounds that selectively block 'serine hydrolases'

Researchers uncover unexpected role of estrogen receptors in brain inflammation

Researchers uncover unexpected role of estrogen receptors in brain inflammation

UCSD scientists discover steroid hormone that inhibits brain inflammation

UCSD scientists discover steroid hormone that inhibits brain inflammation

New method for mapping myelin sheaths of nerve cells

New method for mapping myelin sheaths of nerve cells

Copper intake linked to increased probability of developing Alzheimer's disease

Copper intake linked to increased probability of developing Alzheimer's disease

Conference to discuss process of synaptic plasticity in Alzheimer's disease

Conference to discuss process of synaptic plasticity in Alzheimer's disease

Naurex announces completion of $18 million Series A financing

Naurex announces completion of $18 million Series A financing

Researchers identify mitochondrial proteins that can affect human ageing

Researchers identify mitochondrial proteins that can affect human ageing

UH chemist receives prestigious Sloan award for next-generation computer memory

UH chemist receives prestigious Sloan award for next-generation computer memory

HFA develops free 'Alzheimer's Disease and Hospice Care' online webinar

HFA develops free 'Alzheimer's Disease and Hospice Care' online webinar

EAS receives NIH grant to continue Alzheimer's disease research

EAS receives NIH grant to continue Alzheimer's disease research

New international project to create more mutant genes, address shortage of Cre resources

New international project to create more mutant genes, address shortage of Cre resources

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

New rules regarding hospice stays respond to patients with unpredictable illnesses like Alzheimer's and heart failure

New rules regarding hospice stays respond to patients with unpredictable illnesses like Alzheimer's and heart failure

New technique can reveal fat distribution in healthy human brain

New technique can reveal fat distribution in healthy human brain

New non-invasive blood test may detect early stage Alzheimer's

New non-invasive blood test may detect early stage Alzheimer's

Ecstasy may cause long-term brain damage

Ecstasy may cause long-term brain damage

Busy brain cells can both contribute to and prevent Alzheimer's

Busy brain cells can both contribute to and prevent Alzheimer's

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.